What is HC Wainwright's Forecast for Cybin FY2028 Earnings?

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Cybin Inc. (NYSE:CYBN - Free Report) - Investment analysts at HC Wainwright dropped their FY2028 earnings per share estimates for Cybin in a report issued on Monday, August 18th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of $1.81 per share for the year, down from their prior estimate of $1.88. The consensus estimate for Cybin's current full-year earnings is ($4.76) per share.

CYBN has been the subject of a number of other research reports. Cantor Fitzgerald upgraded Cybin to a "strong-buy" rating in a report on Tuesday, May 13th. Canaccord Genuity Group lowered their price target on Cybin from $73.00 to $70.00 and set a "buy" rating on the stock in a research report on Tuesday, July 8th. One analyst has rated the stock with a Strong Buy rating and three have issued a Buy rating to the company. According to data from MarketBeat, the company has an average rating of "Buy" and an average target price of $85.00.

Cybin Stock Up 3.3%

Shares of NYSE:CYBN traded up $0.23 during midday trading on Tuesday, reaching $7.15. The company had a trading volume of 592,928 shares, compared to its average volume of 320,405. The business's 50 day moving average price is $7.68 and its 200 day moving average price is $7.55. The stock has a market cap of $168.67 million, a PE ratio of -1.63 and a beta of 0.68. Cybin has a 1-year low of $4.81 and a 1-year high of $13.88.

Institutional Investors Weigh In On Cybin

A number of institutional investors have recently made changes to their positions in the company. Cowa LLC boosted its holdings in shares of Cybin by 12.8% during the second quarter. Cowa LLC now owns 13,200 shares of the company's stock worth $111,000 after acquiring an additional 1,500 shares during the period. AdvisorShares Investments LLC increased its stake in Cybin by 3.2% during the 4th quarter. AdvisorShares Investments LLC now owns 50,651 shares of the company's stock worth $447,000 after acquiring an additional 1,567 shares during the period. National Bank of Canada FI increased its stake in Cybin by 3,546.5% during the 1st quarter. National Bank of Canada FI now owns 5,251 shares of the company's stock worth $33,000 after acquiring an additional 5,107 shares during the period. Knott David M Jr increased its stake in Cybin by 10.6% during the 1st quarter. Knott David M Jr now owns 66,880 shares of the company's stock worth $424,000 after acquiring an additional 6,434 shares during the period. Finally, Boothbay Fund Management LLC increased its stake in Cybin by 9.2% during the 4th quarter. Boothbay Fund Management LLC now owns 106,665 shares of the company's stock worth $941,000 after acquiring an additional 9,029 shares during the period. Institutional investors own 17.94% of the company's stock.

Cybin Company Profile

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds.